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INTRODUCTION 
Ischemic heart disease  
Ischemic heart disease is the leading cause of death worldwide [1]. The hallmark of disease is 
formation of atherosclerotic plaques in coronary arteries. The process is initiated by endothelial 
injury and further promoted by inflammation, lipid accumulation, proliferation of smooth muscle 
cells (SMC) and matrix deposition. It starts at an early age, where fatty streaks are seen in 
autopsies of children as young as five years of age [2-4]. Plaques usually consist of a gel-like, 
lipid-rich core covered with a fibrous cap consisting of a layer of sclerotic vessel tissue. It is the 
lipid core which is the more dangerous component because it can increase in size and destabilize 
the plaque [5]. Plaques with increased lipid content are more prone to rupture, leading to the 
intraluminal thrombosis of coronary arteries and consequently acute myocardial infarction or 
sudden death [6, 7]. Approximately 75% of acute coronary syndromes is caused by underlying 
plaque rupture [5]. Well-known risk factors such as high blood pressure, high cholesterol and 
glucose levels may contribute to the process. It is thought infection or inflammation may enhance 
plaque rupture [5, 6]. Currently composition and vulnerability of plaques cannot be revealed by any 
available diagnostic method. However not all plaques are prone to rupture and transformation from 
an asymptomatic fibroatheromatous plaque to a lesion at high risk for rupture, are not fully 
understood and it is a therapeutic window. Patients suffering from coronary artery atherosclerosis 
can get symptoms such as effort angina which is stable, unstable coronary syndrome, which is 
transitory ischemia and at risk for developing infarction, and finally, myocardial infarction with 
thrombus formation  [1-7].     
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Myocardial remodelling 
Initaly, remodelling begins as adaptive response to myocardial injury, which lead to alterations in 
myocardial cell phenotype, myocardial morphology and progressive functional deterioration [8]. It 
is caused by conditions such as myocardial infarction [9], hypertension, aortic stenosis (pressure 
overload) [10], mitral insufficiency (volume overload) [11], myocarditis (inflammatory cardiac 
muscle disease) [12], idiopathic [13] and others. In this overview the focus is on remodelling after 
myocardial infarction since this was the subject of our investigation. Occlusion of a coronary artery, 
if not timely revascularized by percutaneous coronary intervention (PCI), thrombolysis or coronary 
artery bypass grafting, results in regional ischemia and ultimately death of ischemic 
cardiomyocytes [14, 15]. An increased hemodynamic load challenges the remaining 
cardiomyocytes, which first lengthen and then adapt by increasing cell size and number of 
contractile units, with lack of a concomitant effect on muscle cell proliferation [16-21]. Reactivation 
of embryonic gene programs may be important for this process. Increased cell size comes with the 
high price of greater oxygen demand in the already ischemic myocardium, thus further promoting 
loss of remaining cardiomyocytes [16, 22-24]. Remodelling may be further enhanced by 
inappropriate responses of damaged myocardium to neurohormonal stimulation [25, 26]. The left 
ventricular wall thins and the chamber dilates resulting in gradually increasing residual volume and 
decline of ejection fraction [15, 23, 24]. Myocardial integrity is maintained by cardiofibroblasts, 
which proliferate excessively, first in the infarct zone and then beyond, leading to with 
accumulation of collagen and cardiac fibrosis [27-29]. Myocardial infarction induces a sterile 
inflammation and reabsorption of necrotic tissue, also contribute to remodelling [30, 31]. For 
patients that survive the acute phase of myocardial infarction, the rate of remodelling is directly 
proportional to the infarct size [32]. The greater the infarct the more rapid is postinfarction left 
ventricular dilatation and reduction of ejection fraction [33]. An increasing amount of patients suffer 
from heart failure, which is probably due to improved treatment of acute infarction combined with 
an aging population. However, as mortality and morbidity of the heart failure remains unacceptably 
high, it argues for inadequacy of our current therapy. 
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Paradigm shift in treatment of heart failure 
Some 30 years ago, the cardiorenal pathophysiological theory prevailed, and heart failure patients 
were treated with diuretics, vasodilatory and inotropic drugs. In the 1980 the neurohumoral 
understanding took over, leading to use of angiotensin-converting-enzyme inhibitors, beta-
adrenergic antagonists and aldosterone antagonists. Obviously these treatments are inadequate. 
Recent studies are revealing an inflammatory component in progression of heart failure, launching 
the cardioinflammatory model of heart failure [34, 35]. Patients with heart failure have 
progressively elevated levels of inflammatory cytokines, both in the circulation and in the failing 
heart, suggesting activation of the innate immune system secondary to cardiac stress [36-39]. 
Initially it was observed that in contrast to the healthy heart that does not express tumor necrosis 
factor-alpha (TNF), failing heart generates large quantities of TNF. The level of TNF 
expression is directly proportional to the severity of the disease [40, 41]. Experimental studies with 
transgenic mice show that cardiac-specific overexpression of TNFcauses gradual left ventricular 
dilatation and decline in myocardial function [42-44].  Proinflammatory hypothesis of heart failure 
was supported with experimental studies, which show that inhibition of TNF prevents myocardial 
remodeling [45-47]. However, the recent clinical trials designed to suppress TNFresulted in 
worsening of heart failure [48-50] and the inflammatory theory of myocardial remodelling did not 
result in any novel treatments 
 
Current treatments of ischemic heart disease 
The objective in current treatment of ischemic heart disease is to slow down the progression of the 
disease, relieve symptoms, improve quality of life, reduce the need for hospitalization and 
ultimately prolong life. Different therapeutic approaches or combinations are used for targeting 
different components of this complex disease. 
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Reduction of risk factors 
The relationship between atherosclerosis and high blood glucose and cholesterol levels is now 
well established. Perhaps the best therapeutically strategy in treatment of the heart remodeling is 
preventing coronary disease from developing by adopting a healthy lifestyle. Healthy lifestyle 
habits such as low-fat diet [51, 52], limiting alcohol and quitting smoking [53, 54], regular physical 
activity [55, 56] and maintaining a healthy weight [57] have favorable effects and should be 
practiced from the earliest days [58, 59]. However, for most of the patients this is not enough and 
they need pharmacotherapy, with oral antidiabetic agents and cholesterol lowering drugs 
Reducing risk factors with cholesterol and glucose lowering drugs slow down the progression of 
atherosclerosis [60-63]. Statins not only slow down progression, but can also reverse the process 
of atherosclerosis [63-66]. 
 
Surgical alternatives 
For some patients conventional pharmacological therapy is insufficient in preventing 
atherosclerosis of coronary arteries. Revascularization can be performed either by percutaneous 
coronary interventions (PCI) [67, 68] or more invasive open heart coronary artery bypass grafting 
(CABG) [69, 70]. Those procedures reestablish lumen of occluded vessel, for a short while [71, 72]. 
Initially the occurrence of restenosis after PCI was as high as 20-50% [73], while after introduction 
of stents the occurrence of restenosis was dramatically reduced to 5-10% [74]. It still remains a 
significant clinical problem [75]. Patients undergoing CABG compared with PCI of a native vessel 
generally have worse long-term clinical outcome [76]. 
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Treating the failing heart  
Numerous strategies that intervene with inappropriate neurohormonal stimulation are used in 
clinical practice with various degrees of success in the treatment of heart failure. Angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers [77] lower blood pressure, 
improve blood flow and decrease cardiac workload [78]. Beta adrenergic blockers slow the rate of 
contraction, reduce heart rate, lower blood pressure and reduce the risk of heart arrhythmias [79], 
while diuretics prevent accumulation of fluids and maintain blood pressure [80]. When all 
pharmacological strategies fail, the only option is heart transplantation. Even though the survival of 
transplanted patients has greatly improved, the donor is almost never perfect and numerous 
challenges remain: rejection of donor heart, graft infections, unspecific graft failure and sclerosis, 
and long term immunosuppression issues [81-84]. The largest limitation of cardiac transplantation 
is donor availability. 
For patients who are out of options we have been exploring alternative therapeutically approaches 
in treatment of ischemic heart disease.  
 
Potential of retinoic acid in treatment of cardiovascular remodelling 
Retinoic acid metabolic pathway and mechanism of action 
Retinoic acid metabolites exert a wide range of effects on fetal development and cardiac 
morphogenesis, and furthermore on tissue homeostasis, cell proliferation, differentiation and 
apoptosis in postnatal life [85-87]. Mammalian cells cannot synthetize vitamin A (retinoic acid), 
which is obtained from diet in the form of retinyl esters or from -caroten, which are converted to 
retinol and stored in the liver. The homeostasis of vitamin A is strictly regulated, since excessive 
free vitamin A can intervene with cell function and survival. It is delivered to the targeted cells as 
retinol bound to retinol binding proteins (RBPs). RBPs protect both vitamin A from enzymatic 
damage and cells from unregulated diffusion of this potent signaling molecule. RBPs are found 
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both extracellularly and intracellularly. Vitamin A becomes toxic in vivo when it surpasses the 
binding capabilities of RBPs. Furthermore, the vitamin A - RBP complex is recognized by cell 
surface receptors (STRA6), which binds exclusively to RBP and induces release of vitamin A into 
the cell. The RBP-STRA6 system functions as a physiological mechanism of vitamin A uptake [88-
90]. The STRA6 expression level is suggested to be a good predictor of retinol status in the cells 
[91]. Intracellular retinol is in a metabolic cascade converted to the biologically active derivatives 
all-trans RA (atRA), 13-cis RA or 9-cis RA by metabolic enzymes (i.e. oxidation enzymes of the 
ALDH family) [92], which are delivered to the nuclear retinoic acid receptors by cellular binding 
proteins (CRBPs and CRABPs) [93, 94]. Excessive vitamin A is deactivated by conversion into the 
inactive metabolites 4-oxo-RA, 4-OH-RA, 18-OH-RA and 5,8-epoxy-RA by cytochrome p450 
enzymes (CYP26A1 and CYP26B1) [95].  AtRA signals through binding to the nuclear receptor 
RAR (, , or ), while its enantiomer 9-cisRA and 13-cisRA binds to RAR or RXR (, , or ) [96].  
The receptors behave as ligand-activated transcription factors that form heterodimers and bind to 
DNA sequences called retinoic acid respond elements (RAREs), located within the promoter of 
target genes [94, 97]. The heterodimers have two functions; modulate the frequency of 
transcription of target genes after binding to RARE, and cross-talk with other signalling pathways, 
such as thyroid hormone receptors, vitamin D receptors, peroxisomal proliferator-activated 
receptors, and several orphan receptors [94].  
     
Retinoic acid and vascular remodelling 
Percutaneous transluminal angioplasty (PTA) is established as routine procedure for treatment of 
patients suffering from peripheral arterial occlusive disease [98-100]. In principle, a catheter with 
small folded balloon is advanced over the wire to the narrow segment of the vessel that needs to 
be treated. Inflation of the balloon compresses the plaque and dilates the artery, improving the 
blood flow. Restenosis is quite common in PTA and PCI of the coronary arteries. At the cellular 
level, restenosis is characterized by migration and proliferation of local smooth muscle cells (SMC) 
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at the site of endothelial injury, resulting in formation of hyperplastic neointima [101].  Intact 
endothelium plays an important role in vascular homeostasis. Endothelium-derived nitric oxide 
mediates endothelium-dependent vasodilation, inhibits leukocyte adhesion, SMC migration, 
platelet adhesion and aggregation, and the expression of plasminogen activator inhibitor-1, a 
known prothrombotic protein [102]. Reendothelisation after vessel injury and control of SMC 
proliferation were early recognized as phenomenons of importance to reduce the occurrence of 
restenosis. 
Retinoic acid was found to induce proliferation of human umbilical vein endothelial cells (HUVEC) 
in vitro [103], and to accelerate reendothelisation after vessel injury in vivo [104].  It also restricts 
proliferation of SMC in vitro [105-107] and in vivo [105-110]. Control of proliferation of those to 
cells seems to be mediated by signaling through RAR (, , or ).  Anti-proliferative effects of RA 
on SMC and reduction of the occurrence of restenosis was documented across various species 
[105-111] including humans [112]. When administrated orally [110, 113], injected intramuscularly 
[114], injected at the place of vessel injury [115], or endogenously generated [116], RA prevents 
neointimal hyperplasia resulting in a marked reduction of the vessel cross-sectional area and 
reduction of the intimal/medial thickening ratio.    
Probably the most underinvestigated cell which contributes to vascular remodelling is fibroblasts. 
Their migration from adventitia into neointima was observed in several studies [117-119]. One 
study showed that myofibroblasts characterized by the expression of SM -actin also coexpress   
CRBP-1, a retinoic acid–responsive gene [120]. However, effect of RA on vascular fibroblast 
proliferation and migration was not investigated.   
 
Retinoic acid and myocardial remodelling 
The RA signal transduction pathway is recognized as a master regulator of embryonic 
cardiomyocyte proliferation and differentiation [121-123]. Disturbances in RA homeostasis, both 
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lack of and excess of RA, during heart formation may result in congenital cardiovascular 
malformations [124]. Myocardial remodelling is associated with reactivation of embryonic gene 
programs [20, 21, 125]. Postnatal RA signal transduction pathway appears to have role in 
preserving the normally differentiated phenotype of cardiomyocytes and restricting cardiofibroblast 
proliferation and fibrosis. In vitro studies on rat neonatal cardiomyocytes and cardiofibroblasts 
demonstrate that RA can antagonize decrementing hypertrophic stimuli of some major promoters 
of remodelling such as endothelin, angiotensin II and phenylephrine [126-131]. It was observed 
that RA inhibits hypertrophic responses of cardiomyocytes evoked by cyclic stretching [127]. Role 
of RA in maintainance of cardiac structure and function was demonstrated in vivo. RA prevented 
myocardial fibrosis during the development of hypertension in spontaneously hypertensive rats 
[114]. Dietary depletion of RA from tissues resulted in ventricular dilatation and decline of systolic 
function in rats [132]. Tissue insufficiency of RA enhanced remodelling after myocardial infarction 
[133], while supplementation with RA after myocardial infarction attenuated ventricular remodelling 
[134]. The above studies demonstrate a favourable effect of RA on myocardial remodelling. 
However, if RA signaling is activated in the process of cardiac remodelling remains to be 
investigated.    
 
 
Potential of gene therapy in treatment of myocardial remodelling 
For patients where conventional pharmacological therapy is not sufficient and distribution of 
coronary artery disease disallows revascularization, gene therapy may offer an alternative. The 
potential of gene therapy is virtually unlimited. In theory targeting vascular cells could restrict 
proliferation and reoccurrence of stenosis, or promote angiogenesis. Gene delivery to 
cardiomyocytes could antagonize hypertrophic stimuli and promote survival after i.e. myocardial 
infarction. Targeting cardiofibroblasts could perhaps limit fibrosis. Gene therapy has already 
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reached clinical trials [135]. The selection of the gene and method of transfer is determined by the 
therapeutic objective. No matter what the purpose is, the ultimate challenge is safe, sufficient and 
lasting transfer of the selected gene to the targeted cells [136, 137]. DNA encoding for protective 
factors can be injected directly into the myocardium, delivered through the coronary arteries or 
veins, or into the pericardium [137]. However, achieving sufficient nuclear uptake of delivered DNA 
by targeted cells proves to be challenging. Two main gene delivery strategies have emerged over 
the years: non-viral delivery systems and viral vectors [136, 137].  
 
Non-viral gene delivery in treatment of myocardial remodelling 
Non-viral delivery systems are usually plasmid DNA, DNA – liposome complex or different 
polymers used both as protection of DNA from enzymatic damage, and enhanced cellular uptake 
of DNA [138-140]. Those DNA complexes are successfully used in vitro, but with moderate 
success in vivo. Applying those strategies in order to transfer genes with intracellular effects to the 
myocardium appears to be difficult, since successful transfection of a greater number of cells is 
needed [141]. Naked DNA cannot sufficiently penetrate the cells and usually a very local 
transfection is achieved [137, 142, 143], while 99% of DNA which does not enter the cell is 
degraded by endonucleases within minutes [144-147]. The highest transfection efficiency of naked 
DNA in vivo was achieved with direct myocardial injection and it was estimated to reach barely a 
few hundred cells [148]. Despite low transfection efficiency, resulting in a very local expression, 
this approach has been used experimentally and clinically with considerable success [137, 149]. In 
experimental animal models direct myocardial injection of naked DNA into ischemic myocardium 
encoding for transient stromal cell-derived factor-1 alpha [150] or hepatocyte growth factor 
prevented the progression of heart failure [149]. Clinical trials show that injection of DNA encoding 
for vascular endothelial growth factor gene 2 to patients with ischemic heart disease increased 
their tolerance to physical activity [141]. However, injecting DNA into the heart muscle is an 
invasive procedure associated with tissue damage, and due to the hearts’ protective placement in 
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the thorax, is unlikely to represent a large-scale clinical treatment. Use of non-viral delivery 
systems could perhaps be a method of choice for transfection of vascular cells in vivo, since naked 
DNA transfer is not associated with systemic dissemination and inflammation, which are 
considerable risks if vector enters arterial blood [151]. It was demonstrated that adequate gene 
transfer of therapeutic genes into the vascular wall can be achieved using endovascular stents 
coated with different polymers containing DNA [152-154].  
 
 
Viral gene delivery in treatment of myocardial remodelling  
Gene delivery by viral vectors is another approach with high likelihood of success. The principle is 
relying on the natural ability of viruses to recognize, penetrate and deliver their genetic material to 
cells [155]. Viral vectors achieve successful transfection of greater number of the cells within the 
targeted organ than the approaches mentioned in the previous chapter, but with considerable risks 
[156]. The selectivity of viral vectors remains an issue, since viruses usually infect numerous cell 
types [151, 155]. Delivered DNA can practically incorporate into any cell and in any place in the 
human genome resulting with dysfunction or mutation, particularly in cells with high mitotic index.  
Malignant mutations resulting in cancer have been already reported in clinical trials using gene 
therapy. Correction of hematopoietic stem cells, carrying X-linked severe combined 
immunodeficiency, with retrovirus, caused T cell leukemia in 4 of 20 patients [157, 158]. Another 
issue to consider is the possibility of systemic dissemination and inappropriate inflammatory 
responses, which could be life-threatening. Using an adenoviral vector in the treatment of ornithine 
transcarbamylase deficiency at the University of Pennsylvania resulted with the death of a patient. 
This was attributed to the dissemination of the viral vector, massive inflammatory response, 
disseminated intravascular coagulation, acute respiratory distress and multiorgan failure [151, 159]. 
Gene therapy of myocardial remodelling is gaining momentum. Many different viral vectors have 
been tried with various degrees of success and unwanted side effects [160]. Evidence suggests 
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that adenoassociated viruses (AVV) are currently the vectors of choice when targeting 
cardiomyocytes [161-163]. Serotypes AAV 1, 6, 8 and 9 have been recognized to have higher 
tropism for cardiomyocytes than all previous viral vectors used in cardiac gene therapy [163, 164]. 
They are not associated with any human disease and they can be administered systemically. AVV 
9 is very cardioselective with an amazing transfection efficiency of almost 100%, resulting in long 
lasting myocardial expression and virtually no unwanted complications [161, 163, 165, 166]. Even 
though some other organs are transfected, hundreds of patients have been treated without 
observing unwanted effects [135]. Currently under investigation is clinical trial of sarcoplasmic 
reticulum calcium ATPase 2a transfer to the failing ischemic heart, using AVV1 as vector [167].   
 
Remote myocardial protection by injecting naked DNA encoding for HMOX-1 into the 
skeletal muscle   
Remote myocardial gene therapy is a new approach [137, 156, 168]. It is based on the principle of 
remote ischemic preconditioning [137]. The principle refers to the phenomenon by which exposure 
of non-cardiac tissue to episodes of ischemia and reperfusion prior to the cardiac ischemia 
induces myocardial protection. The protection appears universal [169-178]. Remote ischemic 
preconditioning is likely to convey protection through the secretion of the protective factors into the 
blood stream. Direct injection of DNA to transfect skeletal muscle was used efficiently before and it 
is currently considered as the method of choice for DNA based vaccines [168, 179]. If the gene 
transfer is followed by in vivo electroporation, transfection is far more efficient, lasts longer, and 
proves to be potential approach for delivery of genes encoding for secretory factors [141, 168, 180, 
181]. Unlike the genes with intracellular effects, secretory factors can exert their protective effect 
even with much lower transfection efficiency [137, 141]. Gene delivery of hypoxia-inducible factor 
1 alpha (HIF-1) into the skeletal muscle protects against acute and chronic ischemic injury of the 
heart in vivo, ex vivo and in vitro [137, 156, 168]. Injection of DNA encoding for HIF-1 followed by 
electroporation achieved stable, lasting and local expression up to 8 weeks later, with no leakage 
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to any other organ [168]. Others have confirmed that this approach can achieve sustainable 
overexpression up to one year [182]. HIF-1 gene delivery resulted in increased expression of 
heme oxygenase 1 (HMOX-1) in the treated skeletal muscle, and increased circulating levels of 
bilirubin, a downstream product of HMOX-1 [168]. Hypothesizing that HMOX-1 was an important 
factor for the beneficial effects evoked by HIF-1, the HMOX-1 blocker zinc deuteroporphyrin 2,4-
bis-glycol was given together with HIF-1 [168]. This abolished the protective effects of HIF-1 
when hearts were isolated and perfused with global ischemia and reperfusion, suggesting that 
HIF-1 mediates protection through HMOX-1 [168]. HIF-1 delivery also caused a general 
angiogenesis, which may be procarcinogenic in patients. The next step was to investigate if 
remote gene delivery of HMOX-1 could prevent cardiac remodelling and preserve function, without 
causing general angiogenesis.   
HMOX-1 is stimulated by both hypoxia and oxidative stress in various cell types including cultured 
endothelial, cells vascular smooth muscle cells and cardiomyocytes [183-186]. It is a stress-
induced protein which plays a major role in endogenous cellular protection against injury caused 
by adverse stimuli [187-190]. HMOX-1 is an ubiquitous enzyme which metabolizes free heme into 
carbon monoxide (CO), free iron (Fe) and biliverdin [190], which is further rapidly convertetd into 
bilirubin by biliverdin reductase [191]. Anti-oxidative, anti-inflammatory and anti-apoptotic 
properties of HMOX-1 seems to be mediated by those metabolites [192]. Activation of HMOX-1 in 
hypoxic conditions in animal tissues in vivo and cell cultures in vitro is mediated by hypoxia-
inducible factor-1 (HIF-1) [193]. Over the years it was observed that HMOX-1 can be activated 
also by alternative mechanisms, which are different from those activated by hypoxia such as atrial 
natriuretic peptide and angiotensin II [194-197]. Taken together with the findings of Czibik [156, 
168], HMOX-1 was selected as an interesting candidate for remote gene delivery.  
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METHODOLOGICAL CONSIDERATIONS 
 
Human material 
We get exclusive but limited insight into RA signaling in human ischemic and dilated 
cardiomyopathy through obtaining the left ventricular free wall biopsies in different stages of 
disease. Biopsies were collected from patients undergoing coronary artery bypass grafting (CABG, 
n=11). Thru-cut biopsies were taken after cannulation for extracorporeal circulation was completed, 
but prior to cardioplegic arrest. The elective patients had coronary artery disease associated with 
mild cardiac dysfunction graded as NYHA classes I-II with left ventricular ejection fraction >60 %. 
Moreover, biopsies of the left ventricular free wall were also collected from still-beating explanted 
human hearts from patients with end-stage heart failure undergoing cardiac transplantation due to 
postinfarct heart failure (CAD, n=9) or non-ischemic dilated cardiomyopathy (CMP, n=15). The 
patients were in NYHA classes III-IV with ejection fraction <35%. Gene expression was compared 
to donor hearts, which were obtained from sex- and age-matched healthy individuals with no 
history of heart disease, dying suddenly of non-cardiac reasons (DONOR, n=7). The patients are 
heterogenic. Many variables may influence results such as gender, age, past medical history, 
sampling procedure, stage of heart failure. We have control from where we obtain the biopsies, 
but we have no control on the distribution of coronary plaques with in each biopsy. We were not 
able to measure RA metabolite content in the hearts of the patients that were undergoing coronary 
artery bypass grafting, since this would require a fairly large biopsy of left ventricular tissue that 
would undoubtedly harm a patient. In order to investigate gene expression of RA target genes in 
atherosclerotic plaque samples were obtained from 9 patients scheduled for endarterectomy due 
to >80% carotid artery stenosis. Unfortunately, we could not obtain atherosclerotic lesions from the 
coronary arteries. As a control to this, a bit of the renal artery was collected from patients without a 
history of cardiovascular disease scheduled for nephrectomy (n=5). We did not have access to 
normal carotid arteries for comparisons in the same vascular bed. Even though those arteries 
have histologically the same structure as coronary arteries, the different origin of the samples 
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could be a source of variation. In addition, gene expression in the non-sclerotic renal arteries could 
be influenced by the underlying disease.  
 
Animals 
Mice are small, easy to maintain, reproduce quickly and they do not need much space, which 
makes them attractive for research. Genetically they are not more different from humans than any 
other larger animal [198]. The mouse genome has been sequenced revealing that 99% of mouse 
genes have matching human homologs [199, 200]. Until now various transgenic and knockout 
models have been designed to investigate pathophysiology of different human diseases [199, 201, 
202]. Moreover, most mice used in research are inbred, matched in age and gender, which 
reduces genetic variability and make them suitable for lab studies of gene expression. We have 
some examples of experimental studies with mice in preclinical trials which resulted with 
development of successful therapeutic modalities for humans. Often mentioned is the pioneer 
work of Professor Pier Paolo Pandolfi of Harvard Medical School, USA. He used genetically 
engineered mice in order to simulate different types of acute promyelocytic leukaemia. This 
resulted in development of different target therapies which were successfully transferred to 
humans [203]. 
However, there are considerable physiological differences between mice and humans such as 
basal heart rate of 400-600 beats per minute, different responses to some drugs and differences in 
immune cell composition [204]. For our study only male transgenic retinoic acid response element 
luciferase reporter mice and regular C57BL/6 wild type mice were used. We took into 
consideration that female sex hormones could influence results. Estradiol induces retinoic acid 
receptors [205] and interaction between estrogen receptors and RARs has been described [206, 
207]. Gender aspects of RA signaling are scientifically exiting and may be persued in the future. 
Male transgenic retinoic acid response element luciferase reporter mice (RARE-Luc; 
www.cgene.no) of the same weight were used for experiments. RARE-luc mice on C57BL/6 
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background have an artificial construct containing the luciferase gene under the control of three 
copies of RARE derived from the RAR-2. The advantage of this model is that it allows 
observation of RARE mediated transcription in in vivo in real time.  Luciferase was used as a 
reporter to assess the transcriptional activity of RARs. Transcribed luciferase reacts with luciferin 
resulting in photon emission measured in a CCD camera, which is somewhat proportional to the 
degree of RARs activation. Thus, if we would treat the cells with a known RAR agonist such as RA 
we would observe an increase in luciferase readings. Animal models give high control of 
experimental conditions however translation of results to humans cannot be performed. 
Interspecies differences must be considered.  
However, the luciferase model has also some disadvantages. Firstly RARE can be activate by 
retinoic acid, but also by other ligands or post-translational modifications that are present in infarct 
conditions. RARs are known to be a polyvalent cooperator for various nuclear receptors such as 
thyroid hormone receptors, vitamin D receptors, peroxisomal proliferator-activated receptors, and 
several orphan receptors [94]. Moreover, there are at least three RARs isotypes (RAR, RAR 
and RAR). Theoretically if we would like to identify ligand responsible for RARs activation we 
would most likely have to use transgenic animals in which each of the three RAR isotypes have 
been previously knocked down. Furthermore, finding anti-luciferase antibody has shown to be 
almost impossible, preventing us from using immunohistochemistry or bioluminescence 
microscopy.  
  
Mouse model of in vivo permanent ligation of the left coronary artery 
There are several models of remodelling in relation to coronary artery disease which could be 
used: acute myocardial infarction by surgical ligation of left anterior descending coronary artery or 
embolization, myocardial infarction followed by reperfusion and the model of chronic myocardial 
ischemia by permanently ligating the left coronary artery. [208, 209]. A model of chronic 
myocardial ischemia was used to investigate in vivo activation of RARs after myocardial infarction 
and to investigate cardioprotective properties of HMOX-1 (Paper II and paper III). Advantages of 
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this model are low cost and simple procedure. The major limitation of the procedure is that it is 
surgically demanding.   
Mice are anesthetised with isoflurane and intubated. Intubation with mechanical ventilation is 
important step. The ligation procedure requires opening of the chest, which result in disruption of 
negative intrathoracic pressure. Mechanical ventilation is necessary to maintain respiration, and it 
protects the animal from depressive effects of isoflurane on respiratory function. Left-sided 
thoracotomy is performed. The pericardium is cut open, and permanent ligation of the descending 
branch of the left coronary artery is made 1,5 mm under the tip of the left auricle. The challenge is 
to ligate in one quick move so that the heart is not preconditioned and to make even ligations in 
the same place so that infarct size or effect of infarct can be compared between animals. 
Unfortunately, a certain degree of variability exists partly due to individual variations in coronary 
anatomy and partly due to manual factors. In acute models of ischemia this can be corrected 
thorough measuring area at risk (Evans blue staining) [210]. In the chronically infarcted heart this 
cannot be done due to tissue adherances.  Injury to lung parenchyma will result in lethal injury 
which is almost impossible to repair. Avoidance of this requires a well-trained operator and a fairly 
large number of animals. In our hands mortality was around 45%. Subsequently the intercostal 
space, muscles of the external thoracic wall and skin must be sutured leaving no perforations of 
the thoracic wall, so that negative pressure can re-establish, which is essential for recovery of 
spontaneous breathing. Extubation is performed upon spontaneous breathing. Animals were 
placed in a “mini intensive care unit” postoperatively, maintaining an environment of 30°C over 
night. All animals received 0,5 ml saline intraperitonealy prior to surgery to compensate for fluid 
loss and 0,1 mg/kg of Temgesic subcutaneously for analgesia. Sham operated controls were 
included. In sham operation, the surgical procedure is identical, with a suture perforating the heart, 
but no ligation is placed and no infarct is induced. A model of chronic myocardial ischemia was 
used as it allows investigation of not only cardiac protection by assessing area of fibrosis as 
surrogate to infarction area, but it also enable investigation of cellular responses to stress and 
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tissue damage repair. A model of myocardial infarction followed by reperfusion was not used. This 
model is associated with higher mortality rate. 
 
Investigation of retinoic acid target gene expression and proliferation of cardiac cells 
The heart consists of several cell types, where the most abundant are cardiomyocytes and 
cardiofibroblasts followed by endothelial cells and smooth muscle cells. An in vitro approach is a 
good model for dissecting and analysing the response to atRA in various regimes. However, in 
vitro studies are in many ways artificial models, with biological conditions very different from those 
of in vivo. Cells in cultures are not under control of homeostatic mechanisms and control pathways 
which are found in living organisms.  
In paper II we isolated murine cardiofibroblasts and cardiomyocytes using the method established 
by O'Connell [211].  In principle, cells are released from matrix by digestion with collagenase and 
cardiomyocytes are separated from cardiofibroblasts by serial centrifugations [211]. 
Cardiofibroblasts are collected from the first centrifugation, transferred to a separate tube, 
resuspended, and plated. The method takes advantage of cardiomyocyte size, which is 
considerably larger than cardiofibroblast. The advantages of the method is that it gives opportunity 
to investigate gene expression and RA signaling in different cardiac cells, isolated from the healthy 
region of the heart, peri-infarcted zone or the infarct itself. The isolation procedure weakness is 
that the method is highly non-physiological and could affect gene expression, which may no longer 
be representative to the conditions observed in vivo. Further, maintaining cells in culture may alter 
their phenotype. HUVEC and SMC proliferation was evaluated by counting trypsinized cells with a 
hemocytometer (Burker) after 24h and 72h. Cells were counted in triplicates of 5 independent 
experiments. Cardiofibroblasts proliferation in matched time points was evaluated by measuring 
EdU incorporation as a marker of cell division, using flow cytometer. AOSMC and HUVEC were 
purchased as primary cells and proliferation was investigated by manual counting. The major 
drawback for primary cardiomyocytes, which are cells with low stem cell potentiall, is that they 
gradually die off. They are therefore not possible to maintain for more then 24-28 hours. 
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Gene expression  
Through the studies gene expression was evaluated at the mRNA level using real time qPCR. A 
key assumption in studying mRNA expression is that it may predict protein expression. This 
hypothesis was confirmed in mouse experiments by finding increased expression of RBP1 and 
ALDH1A2 at protein level concomitantly with increase of expression of corresponding mRNA. The 
assumption was made on the fact that in eukaryotes export of mRNA from the nucleus is 
mandatory before translation is possible. However, in eukaryotes post-transcriptional modifications 
and RNA degradation play important role in regulation of protein expression in the cell, and protein 
expression should be investigated as the most important end point. In paper I we were not able to 
investigate protein expression in the hearts of the patients undergoing coronary artery bypass 
grafting, as the biopsies obtained with a thru-cut needle were too small. Gene expression was 
examined instead. In paper II as surrogate to protein expression luciferase activity was measured. 
In paper III gene expression of HMOX-1 was confirmed only in treated muscle, and the 
corresponding protein remains to be elucidated. One reason for doing qPCR only in that study is 
that so few cells were transfected and finding representative parts of the muscle for protein 
determination by western blot is cumbersome. Another challenge when investigating relative gene 
expression is choice of proper endogenous control.  The mRNA levels of target gene are related to 
endogenous control according to the standard formula 2-CT, where CT= (CTTarget_sample 
- CTendogenous control _sample)-(CTTarget_calibrator –CTendogenous control_calibrator). The 
endogenous control must be stably expressed and not affected by infarction. Ideally the 
expression levels should be comparable in different cardiac cells. Evaluation of gene expression in 
the mouse material was done using 18S ribosomal RNA. The stability of 18S was tested in our lab 
by comparing gene expression before and after myocardial infarction, which was stable. It is 
considered stable also by others [216-218]. However, 18S is not stable in humans [216] and other 
endogenous controls had to be used. Beta actin was used as endogenous control for HUVEC and 
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AOSMC, while in human heart material hypoxanthine phosphoribosyl transferase was used with 
reference to the literature [216]. 
 
AIMS OF THE STUDY 
 
1. To evaluate the content of retinoic acid metabolites in postinfarct remodelling hearts 
 
2. To elucidate influence of retinoic acid on proliferation of cardiovascular cells 
 
 
3. To investigate a possible activation of retinoic acid receptors in acute myocardial ischemia 
and postinfarction remodelling 
 
4. To evaluate gene expression of the retinoic acid metabolic pathway in acute myocardial 
ischemia and postinfarction remodelling 
 
 
5. To evaluate if remote gene delivery of HMOX-1 prior to myocardial infarction can prevent 
cardiac remodelling and preserve function 
 
6. To evaluate if delivery of DNA encoding for HMOX-1 into the skeletal muscle will induce 
generalised angiogenesis  
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SUMMARY OF RESULTS  
 
Paper I 
Left ventricular biopsies were collected from still-beating explanted human hearts due to dilated 
cardiomyopathy (CMP) or postinfarction heart failure (CAD), and compared with donor hearts 
(Donor). Additional heart biopsies were taken from patients undergoing coronary artery bypass 
grafting (CABG). Atherosclerotic plaques were collected from patients during endarterectomy due 
to >80% carotid artery stenosis and compared to the non-sclerotic renal arteries that were 
collected during nephrectomy from patients without a history of cardiovascular disease. Gene 
expression of key enzymes in RA metabolism was analysed using qPCR. Determination of 
endogenous retinoids in hearts was performed using triple-stage liquid chromatography/tandem 
mass spectrometry. We observed that RA target genes involved in delivery of retinol into the cell 
(RBP1, RBP4 and STRA6) together with genes involved in transformation of intracellular retinol 
into the active forms of retinoic acid (ALDH1A1 and ALDH1A2) were dramatically upregulated in 
hearts of patients with coronary artery disease with stable angina undergoing coronary 
revascularistion, as well as in atherosclerotic lesions. All-trans retinoic acid accumulated in the 
postinfarcted failing human hearts of patients with coronary artery disease. Stimulation of 
cardiomyocytes, cardiofibroblasts, smooth muscle cells, and endothelial cells with atRA increased 
gene expression of the key enzymes governing RA metabolism. Cardiofibroblast and smooth 
muscle cell proliferation was reduced by atRA, which promoted endothelial cell proliferation.  
Coronary artery disease leads to increased expression of key enzymes governing retinoic acid 
metabolism. AtRA accumulated in the failing human heart. All investigated cell types present in the 
heart had induced expression of retinoic acid target genes when stimulated with atRA, which 
influenced cell proliferation.   
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Figure 1. Expression of RA targeted 
genes  and concentration of 
endogenous RA metabolites  
 
Left ventricular biopsies were collected 
from still-beating explanted human 
hearts from patients with end-stage 
heart failure undergoing cardiac 
transplantation due to dilated 
cardiomyopathy (CMP, n=15) or 
postinfarction heart failure (CAD, n=9). 
Explanted healthy donor hearts 
(DONOR, n=7) were controls. 
Endogenous retinoid concentrations 
were measured by triple-stage liquid 
chromatography/tandem mass 
spectrometry. Gene expression of 
retinoic acid target genes was 
investigated with addition of biopsies 
from patients undergoing coronary 
artery bypass grafting (CABG, n=11). 
RNA was extracted and amplified with 
real time PCR. 
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Figure 2. Effect of ATRA on proliferation of cardiac cells. 
 Human aortic smooth muscle cells and human umbilical vein endothelial cells were cultured in 
medium supplemented with 1 M atRA or the dissolvent DMSO. Proliferation of those cells was 
evaluated by counting cells with a hemocytometer. Adult murine cardiofibroblasts were isolated 
from C57BL6 mouse hearts and cultured in medium supplemented with 1 M atRA or the 
dissolvent ethanol. Cell proliferation was evaluated by adding EdU and evaluating incorporation 
with flow cytometry. Data are mean±SD of 4 independent isolations in duplicates   
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Paper II 
Myocardial infarction was induced through ligating the left coronary artery in mice. In vivo cardiac 
activation of the retinoic acid receptors (RARs) was measured by imaging RARE-luciferase 
reporter mice, and analysing RAR target genes by real time qPCR up to six weeks afterwards. 
Endogenous retinoids in postinfarcted hearts were analysed by triple-stage liquid 
chromatography/tandem mass spectrometry. Cardiomyocytes (CM) and cardiofibroblasts (CF) 
were isolated from infarcted and sham operated RARE luciferase reporter hearts and monitored 
for RAR activity and expression of target genes. The effect of atRA on CF proliferation was 
evaluated by EdU incorporation.  
The main finding of this paper was that endogenous RA signaling was activated in the mouse 
heart with permanent coronary artery ligation. A dramatic increase of luciferase signal was found 
in vivo in the thoracic region of RARE-luciferase reporter mice with induced infarction, peaking the 
first postoperative week . The signal was verified to originate exclusively from the heart by ex vivo 
organ imaging, with maximal signal emission in the infarcted zone. This was accompanied by 
increased cardiac gene and protein expression of the RAR target genes retinol binding protein 1 
and aldehyde dehydrogenase 1A2, while gene expression of cytochrome P450 26B1 was 
downregulated. Increased expression of retinol transporting genes coincided with accumulation of 
retinol in infarcted hearts. Cardiofibroblasts and cardiomyocytes isolated from infarcted hearts had 
most RARE-Luc activation, evident as higher luminescence, than those from sham operated 
hearts. This was accompanied by increased fibroblast expression of the RA target genes RBP1, 
ALDH1A2, CYP26B1, RAR and RARwhile RARwas more highly expressed in 
cardiomyocytes. AtRA inhibited proliferation of murine cardiac fibroblasts in vitro. The RA 
signalling pathway is activated in postischemic hearts and may play a role in regulation of damage 
and repair during remodelling. 
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Figure 1: In vivo imaging of cardiac retinoic acid signalling after myocardial infarction 
To evaluate in vivo cardiac activation of the retinoic acid receptor RAR, RARE-luciferase reporter 
mice were subjected to myocardial infarction through permanent coronary artery ligation or sham 
operation (n=7-10 of each). In vivo luciferase activity was measured in a CCD camera after 
injection of luciferin preoperatively and serially after infarction. The digitized luciferase signal is 
quantified and shown as bar graphs (mean±SD). 
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Figure 2: Concentration of endogenous RA metabolites Wild type C57Bl6 mice were 
subjected to in vivo ligation of the left coronary artery or sham surgery, and hearts were sampled 
serially. Endogenous retinoic acid metabolite concentrations were evaluated by triple-stage liquid 
chromatography/tandem mass spectrometry one week after induction of myocardial infarction. 
The infarcted zone of the left ventricle (INF), the periinfarcted zone (PERIINF) and left ventricles 
from sham operated hearts (SHAM) were investigated (n=6). Data are shown as mean±SD. 
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Figure 3: In vitro imaging of retinoic acid signaling after myocardial infarction 
Cardiomyocytes and cardiofibroblasts were isolated from left ventricular tissue from RARE-
luciferase reporter hearts one week after myocardial infarction or sham operation (SHAM). Cells 
were isolated from the infarct (INF) and periinfarct zone (PERIINF). After plating for three hours, 
non-viable cells were removed and luciferin was added for imaging. The upper panel shows a 
representative image of one experiment. The lower panel shows mean±SD of n=5 experiments in 
each group. Note that the Y-axis labelling is different. 
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Paper III 
HMOX-1 was cloned from murine cDNA into pcDNA3.1. C57BL6 mice sedated with isoflurane 
were injected with 15 g of pcDNA3.1/HMOX-1, empty vector, or saline alone into the right 
quadriceps in a total volume of 50 L saline (n=5-8 in each group). Bipolar pulses were used to 
enhance nuclear uptake. The transfection efficacy was evaluated by real time PCR and in situ 
hybridization of the transfected muscle, contralateral muscle, and heart. One week later 
echocardiography was performed using the Vevo 770 System. Mice were subjected to myocardial 
infarction by permanent ligation of the descending left coronary artery, and kept for 6 weeks before 
functional evaluation by echocardiography and tissue harvesting. Cardiac output and cardiac index 
were calculated. The electroporated muscle, the contralateral muscle and the hearts were 
harvested, embedded in OCT and frozen in nitrogen. Concurrently, LV tissue was collected for 
real time PCR analysis of the markers of hypertrophy -skeletal actin, atrial natriuretic peptide and 
brain natriuretic peptide. OCT embedded hearts were sectioned and stained with hematoxylin-
eosin and Masson's trichrome. Infarct size was measured and calculated. Furthermore sections of 
treated quadriceps muscle, contralateral muscle, and hearts were evaluated for angiogenesis 
through staining with the endotelial marker CD31. Quantification was performed using Adobe 
Photoshop CS3.  
Gene delivery of HMOX-1 lead to a local expression of HMOX-1 in the treated muscle, but not in 
any other organ. HMOX-1 treated mice had reduced infarct size and improved function evident as 
higher ejection farction, improved fractional shortening and higher stroke volume. HMOX-1 did not 
cause angiogenesis in the heart or skeletal muscle. 
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Fig 1. Evaluation of cardiac morphology 
Right quadriceps muscles of mice were treated with DNA encoding for HMOX-1, empty vector 
(PcDNA) or saline (Ntc). One week later permanant coronary artery ligation was induced. Six 
weeks later hearts were excised and cross sectioned for histological evaluation of infarct size by 
Masson trichrome staining. When infarct size was quantified, HMOX-1 treated mice had smaller 
infarcts. Values are mean ± SD of n= 7-10 per group. 
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Fig 2.  Cardiac performance 
 Evaluation of cardiac performance in mice after the right quadriceps muscles were treated with 
DNA encoding for HMOX-1, empty vector (PcDNA) or saline (Ntc). Seven days later preoperative 
echocardiography was performed followed by induced myocardial infarction. Six weeks later 
cardiac performance was reassessed by echocardiography. Two-dimensional guided M-mode 
recordings of the left ventricle in the short and long axis viewed at the level of the papillary muscle 
were obtained. Changes in ejection fraction, fractional shortening, stroke volume were calculated. 
All data are presented as mean±SD of n=7-10. 
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GENERAL DISCCUSION 
Retinoic acid in ischemic heart disease 
 
The first two papers in this thesis investigate possible endogenous activation of retinoic acid 
signalling pathway in conjunction with myocardial ischemia and remodelling. We used biopsies 
from human ischemic hearts in different stages of coronary disease, as well as failing hearts due 
to cardiomyopathy, samples of atherosclerotic plaques, a rodent model of in vivo myocardial 
infarction using RARE-luciferase reporter mice and in vitro investigations of RA effects on RA 
target gene expression and proliferation of cardiovascular cells. 
 
Retinoic acid in myocardial remodelling 
 
AtRA in human remodelling 
Gene expression of RA target genes was dramatically upregulated in hearts of patients with 
coronary artery disease with stable angina undergoing coronary revascularistion, as well as in 
atherosclerotic lesions. The gene expression pattern suggests increased retinoic acid delivery in 
ischemic hearts, possibly in an attempt to accumulate retinoic acid metabolites. Upregulation of 
mRNA for RBP1, RBP4 and STRA6 in ischemic hearts could indicate increased activity of the 
RBP-STRA6 system, which are the enzymes involved in physiological vitamin A uptake [88].  
STRA6, which is induced by retinoids, is suggested as a good predictor of retinol status in cells 
[91]. The latter hypothesis was supported by the finding that postinfarcted failing human heart 
accumulated all-trans retinoic acid. Hearts failing due to dilated cardiomyopathy of non-ischemic 
origin had reduced levels of 13-cis retinoic acid, a finding which is difficult to interprete. To our 
knowledge no previous studies addressed the expression pattern of RA targeted genes or 
myocardial content of retinoic acid metabolites in human ischemic heart disease or failing hearts of 
other etiologies. The differences in accumulation atRA versus 13-cisRA may reflect differences in 
the pathophysiology underlying the disease states. RA plays an important role in cardiac 
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morphogenesis during fetal development, and increased RA signalling in failing hearts could be 
due to reactivation of embryonic gene programs, which are reactivated in decrementing 
pathophysiological conditions such as hypoxia, ischemia and hypertrophy. Reactivation of 
embryonic gene programs is associated with cell survival under stress [20, 21]. 
 
AtRA in murine remodelling  
In order to investigate in vivo endogenous activation of the RA signaling pathway in a more 
controlled manner, we subjected RARE-luciferase reporter mice to myocardial infarction. This 
approach revealed for the first time activation of endogenous RA signalling pathway in 
postischemic mouse hearts, which was concomitant with increased expression and translation of 
RA target genes, resulting in accumulation of retinol. It seems to be independent of hypoxia-
inducible factor 1 alpha, as administration of HIF-1 inhibitor in conjunction with infarct induction 
had no effect on the signal. Different metabolites were accumulated in human and mouse hearts, 
which could be attributed to the interspecies differences or different time points of tissue collection. 
Furthermore, the postinfarcted mouse heart was remodelling, but not failing. Thus, the human and 
muse models are not directly comparable.  
Our finding that endogenous RA signalling was activated in the mouse heart with permanent 
coronary artery ligation resulting in retinol accumulation is in a concurrence with a previous study. 
Exogenous administration of radiolabelled vitamin A in conjunction with myocardial infarction 
increased RA in hearts and plasma of rats, while labeled kidney and liver retinol was lower in 
those animals [219]. The authors speculated that it would be beneficial for an ischemic heart to 
increase antioxidant content. However, in that study RA was exogenously administrated, which is 
not physiological and does not reflect endogenous activation of RA signalling in the postinfarcted 
heart. We did not address effects of RA on myocardial remodelling in vivo in the present study. 
Experiments performed by others are arguing for beneficial role of RA in cardiac remodelling [132, 
219]. 
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Role of RARs activation in ischemic hearts   
Activation of RARs in ischemic and postinfarcted hearts may play a role in regulation of damage 
and repair. Studies on rats with tissue deficiency of vitamine A showed that this promotes cardiac 
remodelling and ventricular dysfunction per se [132, 219]. When myocardial infarction was induced 
in rats with tissue vitamin A deficiency, adverse left ventricular remodelling was intensified [133]. 
Conversely, supplementing rats with retinoic acid in a model of tobacco smoke- induced left 
ventricular remodelling prevented remodelling [220]. Retinoic acid supplementation also prevented 
remodelling induced by left coronary artery ligation [134]. The lack of data on human subjects 
makes it difficult to interpret the importance of these data for human pathology. One study 
demonstrates that oral by administered isotretinoin, a first-generation synthetic 13-cis-RA which 
acts systemically and non-selectively can influence cardiac morphology and function in 
investigated patients, evident as increase of ventricular mass and a decrease in the size of the 
chambers [221]. The main weakness of that study is that they lack adequate non treated controls. 
Investigation of RAR response in cardiomyocytes and cardiofibroblasts after myocardial ischemia 
showed that cells from the infarcted RAR reporter hearts had increased luminescence compared 
to cells from sham operated hearts. Expression of RA target genes increased concomitantly with 
luminescence, showing that RARE-luc activation led to transcription of RARE target genes. This 
activation was most abundant in cardiofibroblasts. 
This observation led us to believe that RA signalling may influence proliferation of different 
cardiovascular cells. In support of this hypothesis is the finding of increased expression of RA 
target genes in atherosclerotic plaques, which indicates that the cells within the plaque have been 
stimulated by retinoic acid. This has been suggested before by finding increased transcript levels 
of the retinoic acid receptor responder-1 gene in unstable carotid artery atherosclerotic plaque 
[222]. To explore this possibility the response of RA target genes and cell proliferation was 
investigated in different mouse and human cardiovascular cell types.  
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Effect of atRA on cardiovascular cell types 
AtRA effects on cardiofibroblasts 
All-trans retinoic acid stimulation of mouse cardiofibroblast induced expression RBP1, STRA6, 
CYP26B1, CRABP 1 and RAR, and inhibited cell proliferation, supporting a potential beneficial 
role of atRA during remodelling. Others have studied the effect of atRA on proliferation of neonatal 
cardiac cells. It was observed that hypertrophic responses evoked by cyclic stretching of 
cardiomyocytes was inhibited by atRA [127]. In neonatal cardiofibroblasts, Wang and co-workers 
found that atRA dose dependently reduced angiotensin-induced hyperplasia, and reduced the total 
cell protein content [223]. Wu and collaborators (1996) used atRA to counteract hypertrophic 
responses to endothelin in neonatal cardiomyocytes [129]. We confirm that this applies also to 
adult murine cardiofibroblasts in vitro. The effect of RA on fibroblast proliferation is assumed to be 
benefial, as it would potentially reduce in vivo scar formation in postinfarcted tissue. 
 
AtRA effect on smooth muscle cells 
All-trans retinoic acid stimulation of human AOSMC induced expression of the same genes and as 
expected restricted proliferation. These findings are in agreement those of others. Control of SMC 
proliferation was early recognized as a phenomenon of importance for restenosis and the effect of 
RA on SMC has been investigated. Numerous studies show that RA restricts proliferation of SMC 
in vitro [105-107]. Early in vitro studies performed by Miano in 1996 confirm the presence of 
retinoic acid receptors on SMC, and observed that RA induced activation of RARs, and prevented 
proliferation of SMC induced by platelet-derived growth factor-BB serum [105]. Observations in 
vitro showed that RA can both prevent and promote proliferation of SMC. Interestingly, RA alone 
promoted proliferation of SMC isolated from normal vessels, while it prevented proliferation of 
SMC originating from hyperplastic neointima, evoked by mitogen stimuli [107]. Different response 
of SMC originating from healthy vessel and thickened neointima indicates possible differences in 
SMC phenotype. Further investigations in vitro showed that RA prevents proliferation of SMC 
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induced by some growth factors such as angiotensin II and endothelin [224, 225]. It was later 
documented that RA prevents proliferation signaling through RAR (, , or ). Neuville showed 
that RAR and RAR-alpha agonists, but not RXR agonists, inhibited SMC proliferation [106]. Anti-
proliferative effects of RA was concomitant with upregulated expression of differentiation marker 
genes SM- myosin heavy chain and SM -actin, proposing that RA promotes differentiation of 
phenotypically altered SMC from neointima [226]. Studies performed on the RA inactivating gene 
CYP26B1, showed that silencing the CYP26B1 gene using siRNA or reducing CYP26B1 
enzymatic activity using an inhibitor (R115866) enhanced RA-mediated signalling, resulting in 
reduced proliferation of SMC [116].  
More importantly RA reduces the occurrence of restenosis in vivo [105-110]. Oral administration of 
RA in the rabbit iliac artery atherosclerotic model in conjunction with balloon angioplasty, resulted 
in a marked reduction of the vessel cross-sectional area and reduced the ratio of intimal/medial 
thickening [113]. Chronic RA treatment was found to prevent hypertension-induced thickening of 
intramyocardial and intrarenal arteries in rats [114].  Moreover, local administration of RA 
immediately after vessel injury in a model of experimental atherosclerosis of the rabbit carotid 
artery prevents early neointimal hyperplasia and preserves overall vessel diameter [115]. Similar 
effects on SMC proliferation and neointimal hyperplasia were also observed in a rabbit model of 
vein bypass grafting, where oral administration of RA decreased cell proliferation and increased 
apoptosis in the intima of healing vein bypass grafts [110]. 
 
AtRA effect on endothelial cells 
RA stimulation of HUVEC had similar effects on gene expression, but with different biological 
results on proliferation. The effect of RA on endothelial cell proliferation is controversial. Some 
older studies reported both stimulatory effects [227, 228] and inhibitory effects [229].   
More recent studies demonstrate both that RA and the RAR agonist Am80 induce proliferation of 
human umbilical vein endothelial cells in vitro [103]. In vivo studies indicate that RA treatment 
accelerates reendothelisation after vessel injury in rat balloon-injured aorta [104]. However, the 
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underlying mechanism by which RA reestablishes normal endothelial function remains unknown. 
Intact endothelium plays an important role in vascular homeostasis. Two studies reported that RA 
increases nitric oxide production by endothelial cells [230, 231]. In the first study it was observed 
that both RA and RAR agonist Am580 induced production of nitric oxide in human dermal 
microvascular endothelial cells, while the effect was abolished by the RAR antagonist LE540 [230]. 
In the second study the authors attributed this effect to the upregulation of the dimethylarginine 
dimethylaminohydrolase [231]. 
Unlike cardiofibroblasts, smooth muscle cells, and human endothelial cells, which are actively 
dividing cells, cardiomyocytes do not divide. They could be only studied in a short time frame. We 
observed that RA stimulation induced expression of RA target genes. However we were not able 
to attribute functional effect to this. RA was used before to counteract hypertrophic responses to 
endothelin in neonatal cardiomyocytes [129].  
   
Future perspectives 
The current therapy of ischemic heart disease is based on reduction of risk factors by lowering 
triglycerides, increasing HDL, decreasing LDL, decreasing blood pressure or controlling 
hyperglycaemia, but not on inhibiting proliferative responses of cells involved in cardiovascular 
remodelling. The antiproliferative properties of atRA are already used in the clinics against acute 
promyelocytic leukemia and some forms of acute myeloid leukemia. Perhaps the antiproliferative 
properties of atRA could be used to slow remodeling and preserve function of the cardiovascular 
system.   
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Protecting the heart through delivering DNA encoding for heme oxygenase-1 into skeletal 
muscle 
Remote delivery of HMOX-1 is cardioprotective  
Remote delivery of DNA encoding for HMOX-1 was cardioprotective, evident as preserved cardiac 
structure and function 6 weeks after coronary artery ligation, while angiogenesis was not induced 
by HMOX-1 treatment. In our study overexpression of HMOX-1 was found exclusively in the 
transfected right quadriceps muscle, which is in accordance with previous findings with this model 
of gene delivery [168, 232]. Observed cardioprotective properties of HMOX-1 are supported by 
numerous earlier studies. Transgenic animals overexpressing HMOX-1 have remarkably 
increased tolerance to myocardial ischemia, evident as reduced infarct size, preserved left 
ventricular function and improved recovery after ischemia compared to wild type animals [233-235]. 
Gene deletion of HMOX-1 decreases hypoxic tolerance leading to larger infarctions and more left 
ventricular dilatation when exposed to prolonged hypoxia than wild types [233, 236]. Delivery of 
HMOX-1 using adenoassociated vector prior to induction of ischemia dramatically reduces 
ischemic damage of heart, liver, and skeletal muscle [236]. Modification of mesenchymal stem 
cells with HMOX-1 prior to transplantation into the ischemic heart enhances their survival, 
attenuates left ventricular remodelling, and improves the functional recovery of hearts two weeks 
after infarction as compared with transplantation of naive stem cells [237]. However, this is the first 
report of beneficial effects of remotely delivery of HMOX-1 against myocardial infarction. We were 
not able to find to the direct mechanisms underlying cardioprotection in present study.   
 
Proposed mechanism of action of HMOX-1 
The cardioprotective effects of HMOX-1 may be due to its downstream metabolites. We have 
previously shown that treating HL-1 cells with HIF-1, HMOX-1, carbon monoxide donors, or 
bilirubin protects against induced injury [168]. Evidence suggests that biliverdin is potent 
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antioxidant, which enhances resistance to oxidative injury [239, 240]. Cellular depletion of bilirubin 
by RNA interference with HMOX-1 markedly increases tissue levels of reactive oxygen species 
resulting in apoptotic death of HeLa cells [241]. Furthermore, HMOX-1 appears to be the only 
endogenous source of carbon monoxide in mammalian cells, which is recognised as an 
intracellular signalling molecule involved in vasorelaxation and inhibition of inflammation, 
apoptosis, lipid peroxidation and proliferation of smooth muscle cells [240, 242-245]. Accordingly, 
we and others have found that use of water-soluble carbon monoxide releasing molecules 
promotes cardioprotection in vitro and in vivo. Cardiomyocytes exposed to CORM-3 exhibited 
greater tolerance to hypoxia-reoxygenation and oxidative stress, while isolated mouse hearts 
perfused with buffer containing CORM-3 had improved performance and reduced infarct size [246]. 
A recent study indicates that CO strongly activates c-kit+ stem/progenitor cells after myocardial 
infarction, and promotes the differentiation of c-kit+ cells into vascular smooth muscle cells and 
cardiomyocytes [247]. Iron is known to generate ROS, which could damage various cellular 
components [248, 249]. However, iron generated by HMOX-1 also induces ferritin which 
sequestrates iron from the cell [250250]. Ferritin was shown to be a cytoprotective antioxidant 
[251-253]. The intriguing mechanism of cardioprotection after remote delivery of HMOX-1 into the 
skeletal muscle remains to be elucidated, but it is likely to involve secretion of one or more of the 
discussed molecules into the circulation. 
 
Remote delivery of HMOX-1 did not cause angiogenesis 
We did not find evidence of increased vascularisation after HMOX-1 treatment in our study. 
HMOX-1 is considered to promote angiogenesis [254]. Overexpression of HMOX-1 in ischemic 
mouse hearts or in skeletal muscle after hind limb ischemia promotes neovascularization through 
the induction of vascular endothelial growth factor, stromal cell derived factor-1 and the 
recruitment of circulating progenitor cells [255, 256]. However, in these studies, either transgenic 
animals overexpressing HMOX-1 or viral gene delivery to cardiac muscle was used. In our study 
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we had overexpression of HMOX-1 only in the transfected muscle, where very few muscle fibers 
were transfected. Possibly the amount of HMOX-1 overexpression achieved locally in the 
transfected muscle was insufficient to induce angiogenesis. 
 
Future perspectives 
Gene delivery of HMOX-1 into the skeletal muscle profoundly reduced the adverse effects of 
induced myocardial ischemia. Timely delivery of HMOX-1 with a single injection into the skeletal 
muscle might protect inoperable patients with coronary artery disease from the detrimental effects 
of prolonged or repeated ischemia. The mechanism of protection in this experimental setting 
remains to be elucidated.   
 
CONCLUSIONS 
 
1) Coronary artery disease leads to increased expression of key enzymes governing retinoic 
acid metabolism. 
  
2) AtRA is accumulated in the postinfarcted failing human heart, while 13-cis RA was 
decreased in hearts with dilated cardiomyopathy compared to non failing donor hearts. 
 
 
3) When cardiovascular cells were stimulated with AtRA, expression of RA target genes was 
induced 
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4) AtRA reduced proliferation of mouse cardiofibroblasts and human smooth muscle cells, 
while it promoted proliferation of endothelial cells. 
 
5) In a model of in vivo myocardial infarction in RARE-LUC reporter mice, increased luciferase 
signal was found in the infarcted hearts. 
 
6) Expression of RA target genes increased concomitantly with luminescence, showing that 
RARE-luc activation led to transcription and translation of RARE target genes. 
 
7) Increased expression of RA target genes coincided with accumulation of retinol in infarcted 
mouse hearts. 
 
8) Cardiofibroblasts had higher RAR activation postinfarct than cardiomyocytes.  
 
 
9)  Gene delivery of HMOX-1 lead to a local expression of HMOX-1 in the treated muscle, but 
not in any other organ.  
 
10) Remote delivery of DNA encoding for HMOX-1 was cardioprotective, evident as preserved 
cardiac structure and function. 
 
11) HMOX-1 did not cause angiogenesis in the heart or skeletal muscle.  
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Abstract
Background: All-trans retinoic acid (atRA), an active derivative of vitamin A, regulates cell differentiation, proliferation and
cardiac morphogenesis via transcriptional activation of retinoic acid receptors (RARs) acting on retinoic acid response
elements (RARE).We hypothesized that the retinoic acid (RA) signalling pathway is activated in myocardial ischemia and
postischemic remodelling.
Methods and Findings: Myocardial infarction was induced through ligating the left coronary artery in mice. In vivo cardiac
activation of the RARs was measured by imaging RARE-luciferase reporter mice, and analysing expression of RAR target
genes and proteins by real time RT-PCR and western blot. Endogenous retinoids in postinfarcted hearts were analysed by
triple-stage liquid chromatography/tandem mass spectrometry. Cardiomyocytes (CM) and cardiofibroblasts (CF) were
isolated from infarcted and sham operated RARE luciferase reporter hearts and monitored for RAR activity and expression of
target genes. The effect of atRA on CF proliferation was evaluated by EdU incorporation. Myocardial infarction increased
thoracic RAR activity in vivo (p,0.001), which was ascribed to the heart through ex vivo imaging (p = 0.002) with the largest
signal 1 week postinfarct. This was accompanied by increased cardiac gene and protein expression of the RAR target genes
retinol binding protein 1 (p = 0.01 for RNA, p = 0,006 for protein) and aldehyde dehydrogenase 1A2 (p = 0.04 for RNA,
p = 0,014 for protein), while gene expression of cytochrome P450 26B1 was downregulated (p = 0.007). Concomitantly,
retinol accumulated in the infarcted zone (p = 0.02). CM and CF isolated from infarcted hearts had higher luminescence than
those from sham operated hearts (p = 0.02 and p= 0.008). AtRA inhibited CF proliferation in vitro (p = 0.02).
Conclusion: The RA signalling pathway is activated in postischemic hearts and may play a role in regulation of damage and
repair during remodelling.
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Introduction
Retinoic acid metabolites, the active derivatives of vitamin A,
are involved in tissue homeostasis in health and disease [1].
Retinoic acid (RA) orchestrates signal transduction pathways
regulating embryonic development and cellular differentiation
and proliferation [2]. Vitamin A is obtained from the diet as
retinyl esters, or from provitamin A carotenoids as b-carotene,
which are converted to retinol. Delivery of retinol to cells and
its transformation into active retinoic acid metabolites is
complex. It requires delivery of retinol by retinol binding
proteins (RBPs), transport across the cell membrane by
membrane receptor for plasma RBP (STRA6), synthesis of
biologically active forms by metabolic enzymes (i.e. oxidation
enzymes of the ALDH family) and delivery of metabolites to
nuclear retinoic acid receptors by cellular binding proteins
(CRBPs and CRABPs). Endogenous levels of RA are self-
regulated by cytochrome P450 superfamily of enzymes
(CYP26A1, CYP26B1 and CYP26C1), which convert all-trans
RA (atRA) to hydroxylated inactive forms [3].
Heart failure is an increasing clinical challenge due to improved
treatment of myocardial infarction and a steadily aging popula-
tion. The process of remodelling may be initiated by myocardial
injury such as infarction or pressure- or volume overload [4]. It is
at first an adaptive response to maintain normal function, but
when detrimental stimuli overpower adaptive capacity progressive
decompensation follows. Remodelling is often associated with
activation of fetal gene programs [4]. Our current understanding
of the processes of remodelling and heart failure development is
incomplete, and treatment regimens remain to be improved.
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Vitamine A may play a role in remodelling of the heart. During
early embryogenesis RA orchestrates organogenesis and formation
of the heart across various species [5]. Dietary intake of alpha- and
beta-carotene reduced the risk of acute myocardial infarction in a
case-control study of coronary artery disease patients [6]. In adult
rats, vitamin A deficiency causes left ventricular dilatation
resulting in a decline of cardiac function [7]. Evidence suggests
that supplementation with atRA may prevent left ventricular
dilatation and preserve ventricular function in rats with induced
infarction [8]. RA may oppose various hypertrophic stimuli in vitro
and preserve a normal phenotype of cardiomyocytes [9]. Thus,
atRA may be a therapeutic candidate for the prevention and
therapy of cardiac hypertrophy and remodelling in postnatal life.
However, the endogenous expression pattern of RA target genes in
the acute phase of infarction and in long term remodelling is not
well characterized.
RA exists as the derivatives atRA, 13-cis RA or 9-cis RA. AtRA
exerts its actions mainly through binding to the nuclear receptor
RAR (a, b, or c), while its enantiomer 9-cis RA binds to RAR or
RXR (a, b, or c), [10]. The receptors act as ligand-dependent
transcription factors, and form heterodimers binding to promoter
RAR elements (RARE) [11]. The heterodimers have two
functions; modulate the frequency of transcription of target genes
after binding to RARE, and cross-talk with other signalling
pathways. RXR is a polyvalent cooperator for various nuclear
receptors such as thyroid hormone receptors, vitamin D receptors,
peroxisomal proliferator-activated receptors, and several orphan
receptors [5]. RAR/RXR knockout mice develop different forms
of heart defects dependent on the isoform knocked out, including
heart malformations, defects in the conduction system, and heart
failure [12]. Overexpression of RAR or RXR induces dilated
cardiomyopathy, depresses cardiac function, and causes congestive
heart failure [13].
We hypothesized that myocardial infarction evokes RA
signaling and that RA regulated genes may have effects on
postinfarction remodelling of the heart. A mouse model of in vivo
infarction, RARE-luciferase reporter mice, as well as analysis of
cardiac cells and tissue were used to test the hypothesis.
Materials and Methods
Animals
All experiments were performed according to the Declaration of
Helsinki, and the experiments were approved by the Norwegian
Animal Research Authority. Male C57BL/6 mice (25–30 g) or
male retinoic acid response element luciferase reporter mice
(RARE-Luc) (www.cgene.no) of the same weight were used for
experiments as detailed below. Briefly, fertilized zygotes were
obtained from superovulated C57BL/6 females mated to C57BL/
6 males. Linearized DNA, containing three copies of RARE
derived from the RAR-b2 attached to the luciferase firefly gene
was injected into pronuclei of the zygotes. Zygotes were then
transferred into the oviducts of pseudopregnant mice. All the mice
used in these experiments were heterozygous for the transgene and
back–crossed for more than six generations from founder mice to
C57BL/6 [14].
Induction of in vivo Myocardial Infarction
Mice were anesthetised with isoflurane and intubated, and
surgery was performed as previously described [15]. Mechanical
ventilation was used to maintain a respiratory rate of 135/min
with pure oxygen mixed with 1.5–2.0% isoflurane, and a left-sided
thoracotomy performed. The pericardium was cut open, and
permanent ligation of the descending branch of the left coronary
artery was made 1.5 mm under the tip of the left auricle using 8–0
silk suture. Sham operated mice underwent exactly the same
procedures, except that the silk suture around the coronary artery
was not tightened but rapidly withdrawn. Subsequently the
intercostal space, muscles of the external thoracic wall and skin
were sutured with 6/0 polyester. Extubation was performed upon
spontaneous breathing. Animals were placed in a ‘‘mini intensive
care unit’’ postoperatively, maintaining an environment of 30uC
over night. All animals received 0.5 ml saline intraperitoneally
prior to surgery to compensate for fluid loss and 0.1 mg/kg of
buprenorphine hydrochloride (Temgesic, Schering-Plough AS)
subcutaneously for analgesia. Postoperatively animals were
inspected daily and Temgesic was administrated on the first
postoperative day and later when animal behaviour suggested
pain.
In vivo Imaging of Cardiac Retinoic Acid Signalling
To evaluate in vivo cardiac activation of the retinoic acid
receptors (RAR), luciferase reporter mice were subjected to
myocardial infarction as described above or sham operated
(n = 7–10 in each group). After shaving the ventral thoracoab-
dominal wall, mice were anesthetized with isoflurane (1.5–2.0%)
and luciferase activity was measured in vivo serially after infarct
induction using luciferin (Biosynth, Basel, Switzerland) and an
IVIS 100 CCD camera (Xenogen, CA, USA). Luciferin (200 ml
of 20 mg/mL; Biosynth, Basel, Switzerland) was injected
intraperitoneally, and the thoracic region was imaged 12
minutes later (time span decided after pilot studies). Mice were
imaged prior to infarct induction or sham operation, and
followed up to six weeks after infarction. Data acquisition and
quantification were done with the software Living Image
(Xenogen). Light emission in the thoracic region was quantified
as photons/s/cm2/sr. After the last in vivo imaging six weeks
postinfarction, organs were harvested and imaged ex vivo to
confirm that the signal was from the heart.
Effect of Hypoxia Factor 1a (HIF-1a) Inhibition on
Retinoic Acid Signalling in vivo
In order to investigate if retinoic acid signalling during ischemia
was dependent on HIF-1a, RARE-luc reporter mice (n = 4 in each
group) were injected i.p.with 25 mg/kg of the HIF-1a inhibitor
PX-478 (conc. 250 ug/mL in 0.9% NaCl) or vehicle alone 2 hours
prior to ligation of the coronary artery. The concentration of PX-
478 was chosen based on experiments performed in similar in vivo
models [16,17]. PX-478 was injected daily up to 7 days
postinfarction, and the RARE-luc activity was imaged daily 2
hours after administration of HIF-1a-inhibitor. Imaging of
thoracic RARE luc was performed as described previously, and
7 days postinfarct hearts were extracted for ex vivo imaging.
Infarct size was determined by TTC staining, and the biolumi-
nescent signal was related to infarct size estimated in Photoshop.
Ex vivo Imaging of Cardiac Retinoic Acid Signalling
Additional RARE-luc mice were subjected to myocardial
infarction or sham operation (n= 7–8/group) for organ imaging
one week postinfarction, when the in vivo signal was at its strongest.
Mice were anesthetized with isoflurane, injected with luciferin, and
hearts, lungs, thymus, liver, spleen, pancreas and epidydimal white
adipose tissue were surgically removed. Organs were placed in a
petridish and the luciferase signal measured and quantified in the
CCD camera.
Retinoic Acid in Myocardial Remodelling
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Heart Sampling for Gene Expression
In another series of experiments, C57BL/6 wild type mice were
subjected to in vivo induced infarction or sham operation as
described above, and hearts were sampled serially postinfarction
(after 24 hours, 1 week, 4 weeks, and 6 weeks) for RNA extraction
and amplification of RA-regulated target genes. A control group
without infarction was added (n= 6 to 8 in each group at each
time point).
Western Blot
Protein expression was investigated using western blot technic,
as described in more detail in online supplement (Methods S3).
Tissue samples from infarcted and sham operated hearts one week
after induction of infarction (n= 7 of each) were homogenized in
RIPA lysis buffer (Millipore, Temecula, CA, USA, supplemented
with HaltTM Protease & Phosphatase Inhibitor Cocktail (Thermo
Scientific), and 40 mg protein of each was separated on SDS-
polyacrylamide gels (Criteron, BIoRad) and transferred onto
nitrocellulose membranes (Amersham Biosciences Europe, Ger-
many). Membranes were incubated in TBS +0.1% Tween-20, first
with 5% skimmed milk powder, then over-night at 4uC with goat
polyclonal anti-RBP-1 (1:2500; Cat # PAB6754, Abnova) or
rabbit polyclonal anti-ALDH1A2 (1:1000; Cat # 13951-1-AP,
Proteintech, Manchester, UK). HRP-conjugated secondary anti-
bodies were used to vizualize protein bands on photographic film
by chemiluminescence (ECLplus; Pierce, Rockford, IL, USA).
Scanned images of exposed films and membranes stained with
Ponceau solution for protein loading evaluation, were analyzed
using the Image Quant software, and signal intensity of target
protein bands were related to the Ponceau staining to account for
protein loading and blotting efficiency.
Measurement of Retinoic Acid Metabolites
Infarcted or sham operated RARE luciferase reporter hearts
used for ex vivo luciferase activity were also used for measuring
RA metabolites 1 week postinfarction. The infarcted zone of the
left ventricle was dissected from periinfarcted tissue and samples
were separately snap frozen in liquid nitrogen. The samples
from sham operated hearts were uses for comparison. Heart
samples were homogenized in ice-cold phosphate-buffered saline
with a motorized homogenizer (Pro Scientific, Inc., Oxford,
CT), and retinoids were extracted with ice-cold acetonitrile
containing 13C-labeled atRA as an internal standard (IS). The
concentration of the IS was 10 ng/mL. An aliquot was injected
into a 4000 Q TRAP LC-MS/MS instrument with APCI
ionization (Applied Biosystems, California). The liquid chroma-
tography-mass spectrometry conditions were as described
previously [18], except that the separating column was an
ABZ Plus (75 by 3 mm [inner diameter], 3-mm particles;
Supelco, Pennsylvania). The entire procedure was performed
under red light. Calibration graphs were constructed by linear
least-squares regression analysis, plotting peak area ratios of the
analyte concentration and the IS against the corresponding
concentrations. Quantification was carried out by interpolation
and linear least-squares regression [18].
Isolation and Culture of Adult Mouse Cardiomyocytes
and Cardiofibroblasts
Adult mouse cardiomyocytes and cardiofibroblasts were
isolated from hearts from 5 infarcted and 5 sham operated
RARE-luc reporter mice using the method described by [19].
Cells were isolated for evaluation of RARE reporter gene
activity on the 7th postoperative day as described in more detail
in online supplement (Methods S1). The infarcted and
periinfarcted zone of the left ventricle were dissected and used
for cell isolation in parallel with extracting cells from sham
operated hearts. Hearts were perfused with digestion buffer
containing Collagenase II (Worthington Biochemical, Lakewood,
NJ), and mechanically disrupted. Cardiomyocytes were separat-
ed from cardiofibroblasts by serial centrifugations [19]. Cardi-
ofibroblasts were collected from the first centrifugation, trans-
ferred to a separate tube, resuspended, and plated [20].
Cardiomyocytes were resuspended laminin (BD- biosciences)
coated six-well plates (see online supplement). The cells were
incubated for 3 hours at 37uC in an atmosphere supplied with 2
or 5% CO2, before RARE reporter gene activity was measured
using the same CCD camera as for in vivo/ex vivo imaging after
adding luciferin (100 mL of 20 mg/mL). Finally, cells were
harvested for mRNA isolation and stored at –80uC.
RNA Extraction and Real-time q-PCR
RNA was extracted using RNeasy Mini Kit (QIAGEN inc.)
with an additional phenol-chloroform extraction step and in-
column DNase treatment (QIAGEN). Random hexamers for
priming (3 min at 70uC) were used for reverse transcription of
1 mg of RNA from whole heart extracts and 200 ng of RNA from
isolated cardiomyocytes and cardiac fibroblasts. Reverse tran-
scription was followed by a modified First Strand cDNA Synthesis
Protocol with Superscript III (Invitrogen) and RNasin (Promega)
enzymes and cDNAs were amplified using real-time PCR. Primers
for RAR target genes and endogenous control rpl32 were designed
with Primer Express 3.0 software and are shown in online
supplement (Table S1). SYBR green (Applied Biosystems, Foster
City, CA, USA) was used for detection. A predesigned Real-Time
PCR primer pair and probe (TaqMan Gene Expression Assays,
Applied Biosystems) for detection of 18S rRNA was used as
endogenous control for whole heart extracts, whereas rpl32 was
used as endogenous control for cardiomyocytes and cardiofibro-
blasts after performing pilot studies on endogenous control
suitability. For details of PCR reaction, please see supplementary
material online (Methods S2).
In vitro Evaluation of atRA Effects on Cardiofibroblast
Proliferation
Cardiofibroblasts were isolated from 4 healthy C57BL/6 mouse
hearts. Cells were incubated up to 96 h in medium supplemented
with 1 mM atRA dissolved in ethanol (Sigma Aldrich; St. Louis,
USA) and 10 mM EdU (5-ethynyl-29-deoxyuridine; nucleoside
analogue to thymidine which is incorporated into DNA during
active DNA synthesis). atRA and EdU supplemented medium was
changed every 24 h. Control experiments were performed using
ethanol only. Cells were harvested for proliferation evaluation by
EdU incorporation by flow cytometry as described in more detail
in the online supplement (Methods S4).
Statistics
Repeated measurements of luminescence activity postopera-
tively in the thoracic region were evaluated using repeated
measures ANOVA. The non-parametric Mann–Whitney U test
was used to compare gene expression data, luminescence between
explanted organs and isolated cells, where a non-Gaussian
distribution was assumed. Data are presented as mean 6 SD.
Differences were considered significant when P,0.05 and a
tendency was regarded when P was 0.05–0.08.
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Results
Thoracic Retinoic Acid Signalling is Activated Early after
Myocardial Infarction
RAR luciferase reporter mice were used to determine if RA
signalling measured as luminescence was activated in the heart
after induced infarction through in vivo imaging. The RAR
reporter activity was increased in the thoracic region of infarcted
animals, indicating activation in the heart. Infarction-induced
thoracic RAR activity reached the highest level at the end of the
first postoperative week and gradually declined, but remained
higher than sham throughout the six weeks observation period
(Fig. 1).
Retinoic Acid Signalling is Independent of Hypoxia-
inducible Factor 1a
RARE-luc activity was measured and quantified in RARE luc
reporter mice treated daily with the HIF-1a inhibitor PX-478 or
saline in conjunction with infarct induction. No differences were
found between groups during 1 week observation (Figure S1).
Retinoic Acid Signalling was Increased Specifically in the
Infarcted Heart
Since in vivo signalling in the thoracic region could be of non-
cardiac origin, selected organs were harvested and imaged in
the CCD camera to verify the source of signal. One week
postinfarction, when the in vivo signalling peaked, the RAR
reporter activity was higher in infarcted hearts than in sham
operated hearts (Fig. 2). There were no differences in
luminescence between groups in any of the other imaged
organs (Fig. 2). RAR reporter activity remained higher in
infarcted hearts than in sham operated hearts six weeks
postinfarct (results not shown).
Increased in vivo Expression of RA Target Genes
Other mice were subjected to in vivo infarction or sham
operation for sampling of hearts for RNA extraction and
amplification with real time PCR 24 hours, 1, 4 and 6 weeks
postinfarct. Expression of RBP1 mRNA was increased one week
postinfarction (Fig. 3a). ALDH1A2 was increased compared with
sham 24 hours and 1 week postinfarction (Fig. 3b). CYP26B1
tended to be downregulated early post infarction and 4 weeks later
(Fig. 3c). STRA6, CRABP1, CRABP2 and RAR a,b,c, were
unchanged (data not shown).
Increased Expression of RA Transporting and
Metabolising Proteins
To investigate whether retinoic acid transporting and metab-
olizing proteins are induced after myocardial infarction, we
extracted proteins from infarcted and sham operated hearts one
week after coronary artery ligation for western blotting with
antibodies against RBP1 and ALDH1A2. Protein expression of
RBP1 and ALDH1A2 were significantly upregulated in infarcted
hearts one week after infarct, but not in sham operated hearts
(Fig. 3d).
The Infarcted Myocardium Accumulates Retinol
Investigation of endogenous RA metabolite concentrations in
infarcted and sham operated RARE-luc hearts one week later
by triple-stage liquid chromatography/tandem mass spectrome-
try showed accumulation of retinol in infarcted hearts. Increased
levels of retinol were found in the infarcted tissue itself and not
in the periinfarct zone or in sham operated hearts (Fig. 3e).
Retinal, 13-cis RA or atRA were unchanged (data not shown).
Cardiofibroblasts are the Major Source of Luminescence
in the Infarcted Heart
Cardiomyocytes and cardiofibroblasts were isolated from the
infarcted area and the periinfarct zone of infarcted hearts, or
from sham operated RARE-luc reporter hearts. Luciferase
activity was measured after plating of cells. Fibroblasts isolated
from the infarcted zone of infarcted hearts had increased
luminescence compared with fibroblasts from sham operated
hearts (Fig. 4). Luminescence was similar in cells harvested from
the periinfarcted zone and the infarct zone. Hardly any
luciferase activity was detected in cardiomyocytes of sham
Figure 1. In vivo imaging of cardiac retinoic acid signalling after myocardial infarction. To evaluate in vivo cardiac activation of the retinoic
acid receptor RAR, RARE-luciferase reporter mice were subjected to myocardial infarction through permanent coronary artery ligation or sham
operation (n = 7–10 of each). In vivo luciferase activity was measured in a CCD camera after injection of luciferin preoperatively and serially after
infarction. A representative image of an infarcted and a sham-operated mouse is shown on the left (A). On the right, the digitized luciferase signal is
quantified and shown as bar graphs (B; mean6SD).
doi:10.1371/journal.pone.0044740.g001
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operated mice, while the signal intensity increased after
infarction with no differences between infarcted and periin-
farcted cells (Fig. 4).
Gene Expression of RA Target Genes in Infarct Zone is
Higher in Cardiofibroblasts than in Cardiomyocytes
The cells isolated from the infarct zone of hearts used for
RARE-luc activation were used for RNA extraction and
amplification of RA target genes through real time PCR. The
CT value of the endogenous control rpl32 was similar in both
cell types. In accordance with increased luciferase activity in
cardiofibroblasts, gene expression of RBP1, CYP26B1,
ALDH1A2, RARa and RARc was higher in cardiofibroblasts
than in cardiomyocytes. RARb was the only examined gene
which was more highly expressed in cardiomyocytes (Fig. 5a).
In vitro Evaluation of atRA Effects on Cardiofibroblast
Proliferation
Incubation of cardiofibroblasts with 1 mM atRA inhibited cell
proliferation in vitro when EdU incorporation was evaluated 96
hours later by flow cytometry (Fig. 5b).
Discussion
The main finding of the present study was that the RA
signalling pathway was activated in the mouse heart with
permanent coronary artery ligation. Using a reporter mouse with
firefly luciferase coupled to RA response element, a dramatic
increase of luciferase signal was found in vivo in the thoracic region
of mice with induced infarction, peaking the first postoperative
week. The signal was verified to originate exclusively from the
heart by ex vivo organ imaging, with maximal signal emission in the
infarcted zone. This was accompanied by increased cardiac
expression of genes and proteins involved in regulation of RA
Figure 2. Ex vivo imaging of cardiac retinoic acid signalling after myocardial infarction. To verify that the signal in the thoracic region
detected in vivo originated from hearts, organs were harvested one week after infarction or sham operation following in vivo luciferin injection in
RARE-luciferase reporter mice. Organs were placed in a petridish and the luminescence signal quantified. A representative image of one single
experiment is shown on the left (A), where hearts, thymus, gastrointestinal tract (GI-tract), liver, lungs, pancreas, spleen and epididymal white adipose
tissue from one infarcted and one sham operated animal are shown. When the signal was quantified from 6 independent experiments, the
luminescence was exclusively increased in infarcted hearts, and not in sham operated hearts or any other organs (B). Data are shown as mean6SD.
doi:10.1371/journal.pone.0044740.g002
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metabolism RBP1 and ALDH1A2, while CYP26B1 mRNA, an
endogenous enzyme responsible for atRA degradation, was
downregulated. Increased gene and protein expression of retinol
transporting proteins coincided with accumulation of retinol in
infarcted hearts. Cardiofibroblasts and cardiomyocytes had
RARE-Luc activation postinfarct, and increased fibroblast expres-
Figure 3. Expression of retinoic acid target genes and endogenous metabolites after infarction. Wild type C57Bl6 mice were subjected
to in vivo ligation of the left coronary artery or sham surgery, and hearts were sampled serially for RNA extraction and amplification of retinoic acid
target genes with real time PCR, or proteins were extracted for western blotting. Hearts were also sampled from mice without any surgery
(preoperative). Gene expression of retinol binding protein 1 (RBP1) (A), aldehyde dehydrogenase 1A2 (ALDH1A2) (B), and cytochrome p45026B1
(CYP26B1) are shown (C). (n = 6–8 in each group at each time point). D) Representative western blot analysis of retinoic acid transporting and
metabolizing proteins one week after induction of infarction or sham operation. Ponceau solution was used as protein loading (control). Histograms
show the relative density of RBP1 at 16 kDa and ALDH1A2 at 53–57 kDa in infarcted and sham operated hearts. E) Endogenous retinoic acid
metabolite concentrations were evaluated by triple-stage liquid chromatography/tandem mass spectrometry one week after induction of myocardial
infarction. The infarcted zone of the left ventricle (INF), the periinfarcted zone (PERIINF) and left ventricles from sham operated hearts (SHAM) were
investigated (n = 6). Data are shown as mean6SD.
doi:10.1371/journal.pone.0044740.g003
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sion of the RA target genes RBP1, ALDH1A2, CYP26B1, RARa
and RARc, while RARb was more highly expressed in cardio-
myocytes. AtRA inhibited proliferation of cardiofibroblasts in vitro.
Anti-proliferative effects of atRA in cardiac fibroblasts is clinically
appealing, as dietary RA supplementation is easy to perform in
humans with myocardial infarction. The antiproliferative proper-
ties of atRA are already used in the clinics as treatment of different
leukemias.
To our knowledge, no previous studies have reported activation
of retinoic acid signalling in the heart in conjunction with
myocardial ischemia and remodelling. It seems to be independent
of hypoxia-inducible factor 1 alpha (Fig. S1). The increased
RARE-luc activity as well as increased expression of retinol
transporting genes and proteins could lead to cardiac accumula-
tion of retinoic acid postinfarction. This hypothesis was supported
by the finding of altered content of retinol in postinfarcted hearts
in the current study. Our findings concur with one previous study
investigating RA content in postischemic hearts. Palace and
coworkers injected postinfarcted rats with radiolabelled vitamin A.
Radiolabelled vitamin A was increased in hearts and plasma of
rats with myocardial infarction, while labelled kidney and liver
retinol was lower in those animals. The authors speculated that it
would be beneficial for an ischemic heart to increase antioxidant
content. However, accumulation of exogenously administrated
atRA does not necessarily reflect the role of endogenous atRA
postinfarction.
Activation of RARs in the post ischemic heart may play a role in
regulation of damage and repair. We did not address the role of
retinoic acid in vivo in the present study. This has previously been
done by others: Rats with tissue insufficiency of vitamin A had
spontaneous cardiac remodelling and ventricular dysfunction [7].
When myocardial infarction was induced in rats with tissue
vitamin A deficiency, adverse left ventricular remodelling was
intensified [21]. Supplementing rats with retinoic acid in a model
of tobacco smoke-induced left ventricular remodelling could
prevent remodelling [22]. Retinoic acid supplementation could
also prevent remodelling induced by left coronary artery ligation
[8].
The heart consists of several cell types, where cardiofibroblasts
and cardiomyocytes are the most abundant. To explore the relation
between cell types and RAR response, cardiomyocytes and
cardiofibroblasts were isolated from infarcted hearts. Interestingly,
cardiofibroblasts isolated from the infarcted or periinfarcted zones
had increased luminescence compared to fibroblasts from sham
Figure 4. In vitro imaging of retinoic acid signaling after myocardial infarction. Cardiomyocytes and cardiofibroblasts were isolated from
left ventricular tissue from RARE-luciferase reporter hearts one week after myocardial infarction or sham operation (SHAM). Cells were isolated from
the infarct (INF) and periinfarct zone (PERIINF). After plating for three hours, non-viable cells were removed and luciferin was added for imaging. The
upper panel shows a representative image of one experiment (A). The lower panel shows mean6SD of n = 5 experiments in each group (B). Note
that the Y-axis labelling is different.
doi:10.1371/journal.pone.0044740.g004
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operated hearts. RAR luciferase activity increases also in cardio-
myocytes from infarcted and periinfarcted tissue. Fibroblasts had a
higher increase of RA target genes than myocytes. Unlike the
cardiomyocytes, which have low stem cell potential, cardiofibro-
blasts are actively dividing and differentiating.
Cardiofibroblasts stimulated with atRA had reduced cell
proliferation, supporting a potential beneficial role of atRA during
remodelling. Others have studied the effect of atRA on
proliferation of neonatal cardiac cells: The hypertrophic response
evoked by cyclic stretching of cardiomyocytes was inhibited by
atRA [23]. Wu and collaborators used atRA to counteract
hypertrophic responses to endothelin in neonatal cardiomyocytes
[24]. In neonatal cardiofibroblasts, Wang and co-workers found
that atRA dose-dependently reduced angiotensin-induced hyper-
plasia, and reduced the total cell protein content [9]. We confirm
that anti-proliferative effects of atRA applies to adult cardiofibro-
blasts in vitro.
Conclusions
All-trans retinoic acid (atRA) is used in therapy and prevention
of many proliferative diseases such as prostate cancer or acute
promyelocytic leukemia [25]. Because of their important role as
regulators of cellular growth, differentiation, morphogenesis and
metabolism, retinoic acid metabolites may also be of use to modify
the proliferative response of cardiac cells in the process of
remodelling. However, their mechanism of action and potential
use as an anti-remodelling intervention in humans remain to be
investigated.
Supporting Information
Figure S1 Retinoic acid signalling is independent of hypoxia-
inducible factor 1a (HIF-1a). RARE-luc activity in thorax was
measured and quantified in mice treated daily with the HIF-1a
inhibitor PX-478 or saline in conjunction with infarct induction.
No differences were found between groups. Data are mean values
of n= 4 in each group.
(EPS)
Table S1 Primer sequences of the investigated genes.
(XLS)
Methods S1 Isolation and culture of adult mouse cardiomyo-
cytes and cardiofibroblasts.
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Methods S2 Evaluation of RA target genes expression using
Real-time polymerase chain reaction.
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Methods S3 Evaluation of RA transporting and metabolizing
proteins expression using western blot.
(DOCX)
Methods S4 In vitro evaluation of atRA effects on cardiofibro-
blast proliferation.
Figure 5. Expression of retinoic acid target genes in the infarct zone and effects on cardiofibroblast proliferation. A) Gene expression
of retinoic acid target genes in cardiofibroblast (CF) and cardiomyocytes (CM) isolated from left ventricles of infarcted RAR-luciferase reporter hearts 1
week after infarction. RNA was extracted from cells from the infarcted zone and amplified with real time PCR using primers specific for retinol binding
protein 1 (RBP1), cytochrome P450 26B1 (CYP26B1), aldehyde dehydrogenase 1A2 (ALDH1A2), and retinoic acid receptors alpha, beta and gamma
(RAR a,b,c). The figure shows test gene expression relative to expression of rpl32, which was similar in both cell types. Data are mean6SD of n = 5
experiments in each group. B) Cardiofibroblasts were isolated from C57BL6 hearts and cultured in medium supplemented with 1 mM all-trans retinoic
acid (atRA) and 10 mM EdU, as indicator of cell division. After 96 hours, EdU incorporation was evaluated by flow cytometry. Data are presented as
mean6SD of n= 4 in each group.
doi:10.1371/journal.pone.0044740.g005
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